Wegovy Pill Approved in Australia: A New Alternative to Weight-Loss Injections
A significant development in medical weight management has arrived in Australia with the Therapeutic Goods Administration (TGA) approval of Wegovy tablets (oral semaglutide). The new formulation offers an alternative to the weekly injections traditionally used for prescription-based weight management.
For people who dislike needles, find injections inconvenient or prefer taking medication in tablet form, oral Wegovy represents an important additional treatment option.
Wegovy contains semaglutide, the same active ingredient found in injectable Wegovy and Ozempic. It works by mimicking the naturally occurring GLP-1 hormone, helping regulate appetite, increase feelings of fullness and reduce food intake.
Four tablet strengths have been registered in Australia:
- 1.5 mg
- 4 mg
- 9 mg
- 25 mg
Although TGA registration is an important regulatory milestone, actual pharmacy availability depends on commercial supply arrangements.
For patients in Surry Hills, Darlinghurst, Paddington, Redfern, Waterloo, Woollahra and Green Square, understanding the potential benefits, limitations and safety considerations of this new treatment is important when considering medical weight management. Our Surry Hills doctors team explains how Wegovy Oral works, the effectiveness and commonly asked questions.
- What Is Wegovy and How Does It Work?
Wegovy contains semaglutide, a medication belonging to a class known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). GLP-1 is a naturally occurring hormone released by the intestine after eating. It plays an important role in appetite regulation, digestion and blood glucose control. Semaglutide mimics this hormone and produces several effects:
Reduces appetite: Semaglutide acts on appetite-regulating areas of the brain, helping reduce hunger and food cravings.
Increases fullness: It slows gastric emptying, meaning food remains in the stomach for longer and patients may feel satisfied after smaller meals.
Reduces calorie intake: By decreasing hunger and increasing satiety, patients may find it easier to reduce their overall food intake.
Improves blood glucose regulation: Semaglutide stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon when blood glucose is elevated.
The new tablet contains the same active ingredient as injectable Wegovy. The main difference is how the medicine is administered and absorbed. Because semaglutide is a peptide, it is normally broken down in the digestive system. The oral formulation incorporates an absorption-enhancing technology that helps the medication enter the bloodstream through the stomach lining.
This explains why oral Wegovy requires specific administration instructions and why its tablet strengths are substantially higher than the doses used in weekly injections.
- What GLP-1 Weight-Loss Treatments Are Available in Australia?
Before oral Wegovy, most prescription GLP-1-based weight-management treatments required injections.
The main treatments include:
Wegovy injections (semaglutide)
Ozempic injections (semaglutide)
Mounjaro injections (tirzepatide)
Saxenda injections (liraglutide)
- Why Choose a Tablet Instead of an Injection?
One of the main advantages of oral Wegovy is that it removes the need for injections.
Some patients experience needle anxiety or simply dislike administering medication through the skin. Others find it inconvenient to manage injection devices, storage requirements and weekly dosing schedules.
Potential benefits of the tablet include:
- No needles: Avoids self-injection and injection-site reactions such as bruising, redness and irritation.
- Convenience: A daily tablet may be easier to incorporate into some patients’ routines.
- Travel: Patients do not need to organise weekly injections, although they must maintain their daily dosing schedule.
- Patient preference: An oral option may make medical treatment more acceptable to people who would otherwise avoid injectable medication.
However, the tablet is not necessarily easier for everyone. It must be taken under strict conditions each morning, whereas injectable Wegovy is administered once weekly. The best option depends on individual preferences, medical history, treatment goals and ability to follow administration instructions.
- How Should Wegovy Tablets Be Taken?
Oral semaglutide has relatively low and variable absorption. Food, beverages and other medications can interfere with how much medicine enters the bloodstream.
According to the US manufacturer’s instructions, patients should:
- Take one tablet first thing in the morning on an empty stomach.
- Swallow it whole with a small amount of plain water.
- Do not crush, chew, split or dissolve the tablet.
- Wait at least 30 minutes before eating breakfast.
- Avoid other beverages during this waiting period.
- Wait at least 30 minutes before taking other oral medications.
The US instructions specify no more than approximately 120 mL of plain water.
The tablet should not be taken with coffee, milk, juice or breakfast.
The absorption-enhancing formulation is designed to work under specific conditions. Taking it with food or other beverages may compromise absorption.
Patients taking medication for blood pressure, cholesterol, diabetes or thyroid conditions should discuss their morning medication schedule with their doctor. Prescribed medicines should not be discontinued or rearranged without medical advice.
Patients should follow the final Australian Consumer Medicine Information (CMI) and Product Information (PI) once available, as Australian instructions take precedence over overseas guidance.
- What Are the Wegovy Tablet Strengths and Recommended Dosages?
Four tablet strengths have been registered in Australia: 1.5 mg, 4 mg, 9 mg and 25 mg.
Treatment follows a gradual dose-escalation schedule. The purpose is to allow the body to adjust to semaglutide and reduce gastrointestinal side effects.
The US prescribing schedule provides the following framework:
| Treatment period | Daily dose | Purpose |
| Days 1–30 | 1.5 mg | Initial dose |
| Days 31–60 | 4 mg | First escalation |
| Days 61–90 | 9 mg | Second escalation |
| Day 91 onwards | 25 mg | Maintenance dose |
The final Australian dosing instructions may change when released and should be checked against the Australian Product Information.
Why start at 1.5 mg?
The initial dose is deliberately low. Semaglutide affects appetite, digestion and gastric emptying. Starting at a lower dose allows the digestive system to adjust and can reduce nausea, bloating and other gastrointestinal symptoms.
Why increase to 4 mg and 9 mg?
Gradual increases provide progressively greater exposure to semaglutide while allowing patients to adjust to its effects. Patients experiencing significant gastrointestinal symptoms may need a longer period at their current dose.
Why is 25 mg the maintenance dose?
The 25 mg daily tablet is the recommended adult maintenance dose in the US prescribing information. It is the dose investigated in the OASIS 4 clinical trial, which demonstrated clinically meaningful weight reduction.
However, reaching 25 mg should not be treated as an automatic requirement regardless of tolerability. A doctor should assess treatment response, adverse effects and the applicable Australian prescribing instructions.
The goal is to achieve sustainable health improvements while minimising side effects, rather than simply reaching the highest dose as quickly as possible.
- Is the Wegovy Pill as Effective as the Weekly Injection?
Clinical research suggests that oral semaglutide 25 mg can produce substantial weight loss and similar results to injectables. However, it is important to distinguish between evidence that a medication works and evidence that two formulations are equally effective.
The OASIS 4 clinical trial
The OASIS 4 study, published in the New England Journal of Medicine in 2025, investigated oral semaglutide 25 mg in adults with overweight or obesity without type 2 diabetes.
After 64 weeks, estimated average weight changes were:
- Oral semaglutide 25 mg: 13.6% reduction.
- Placebo: 2.2% reduction.
Both groups also received lifestyle intervention.
These findings demonstrated that oral semaglutide produced significantly greater weight reduction than placebo.
How does this compare with injectable Wegovy?
The STEP 1 clinical trial investigated injectable semaglutide 2.4 mg weekly in adults with overweight or obesity.
After 68 weeks, participants experienced an average weight reduction of approximately 14.9%, compared with 2.4% in the placebo group.
| Clinical trial | Formulation | Average weight reduction |
| OASIS 4 | Oral 25 mg daily | 13.6% |
| STEP 1 | Injection 2.4 mg weekly | 14.9% |
These results are encouraging because they suggest oral semaglutide can achieve weight-loss outcomes in a similar general range to injectable Wegovy. However, these were separate clinical trials involving different participants, treatment durations and study designs. They were not direct head-to-head comparisons.
Consequently, it is not scientifically accurate to claim that the tablet is equally effective as the injection. The evidence supports oral semaglutide as an effective weight-management treatment, but individual results will vary.
Mounjaro is another important treatment option. Because tirzepatide acts on both GIP and GLP-1 receptors, its clinical results cannot be directly compared with semaglutide using separate trial percentages alone.
- Can Wegovy Be Taken With Ozempic, Mounjaro or Other GLP-1 Medicines?
No. Concomitant use of Wegovy (semaglutide) tablets or Wegovy (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
This includes combining:
- Wegovy tablets with Wegovy injections.
- Wegovy with Ozempic.
- Wegovy with Saxenda.
- Wegovy with Mounjaro.
- Wegovy with other semaglutide-containing products.
These medicines have overlapping pharmacological effects. Combining them may increase the likelihood of adverse effects, particularly gastrointestinal problems, without establishing additional clinical benefit. Potential complications include severe nausea, vomiting, diarrhoea and dehydration.
Patients already taking an injectable GLP-1 medicine should speak with their treating doctor before changing treatment. A planned transition from an injection to a tablet may be appropriate for selected patients, but the timing and dosing must be determined by their prescribing doctor.
- What Are the Side Effects of Oral Wegovy?
Although the tablet avoids injection-related discomfort, it does not eliminate the systemic side effects associated with semaglutide.
Common side effects include:
- Nausea and vomiting.
- Diarrhoea or constipation.
- Abdominal discomfort.
- Bloating and indigestion.
- Reflux and belching.
- Reduced appetite.
These symptoms are often more noticeable when starting treatment or increasing the dose.
Less common but potentially serious complications include:
Pancreatitis: Severe or persistent abdominal pain, particularly pain radiating to the back, requires urgent medical assessment.
Gallbladder problems: Gallstones and gallbladder inflammation may occur. Symptoms can include upper abdominal pain, nausea and fever.
Dehydration and kidney problems: Persistent vomiting or diarrhoea can lead to dehydration and acute kidney injury.
Hypoglycaemia: The risk is particularly relevant for patients with diabetes who also take insulin or sulfonylureas.
Delayed gastric emptying: Semaglutide slows stomach emptying and may be unsuitable for patients with certain gastrointestinal conditions, including severe gastroparesis.
Allergic reactions: Serious hypersensitivity reactions are possible, although uncommon.
Patients should discuss their medical history, including previous pancreatitis, gallbladder disease, kidney impairment, diabetic retinopathy and significant gastrointestinal problems, before commencing treatment.
Semaglutide should not be used for weight reduction during pregnancy. Patients planning pregnancy should discuss discontinuation well in advance with their doctor.
Patients should also inform their anaesthetist before procedures involving general anaesthesia or deep sedation because delayed gastric emptying can increase aspiration risk.
- Who Is Suitable for Medical Weight-Loss Treatment?
Prescription weight-management treatment is intended for eligible patients rather than anyone wishing to lose a few kilograms.
Common adult eligibility criteria for chronic weight management include:
- BMI of 30 kg/m² or above; or
- BMI of 27 kg/m² or above with at least one weight-related medical condition.
Relevant conditions may include hypertension, dyslipidaemia and obstructive sleep apnoea.
BMI is only one component of a comprehensive medical assessment.
A doctor should also consider weight history, waist circumference, blood pressure, blood glucose, cholesterol, liver and kidney health, existing medications, lifestyle and previous weight-management attempts.
The decision to prescribe medication should be individualised.
- Why Lifestyle Changes Remain Essential
Weight-loss medication does not replace healthy eating and regular physical activity. Oral semaglutide is intended to complement a reduced-calorie eating plan and increased physical activity.
A comprehensive programme should include:
Nutrition: A balanced diet containing adequate protein, vegetables, fruit, wholegrains and healthy fats. Reduced appetite makes it particularly important to maintain adequate nutrition.
Resistance training: Strength exercise helps preserve muscle mass during weight reduction.
Cardiovascular exercise: Walking, swimming and cycling can improve cardiovascular fitness and metabolic health.
Long-term maintenance: Weight regain can occur after stopping treatment. Sustainable lifestyle changes and ongoing support are important for maintaining improvements.
- How Can Your GP Help With Medical Weight Management?
Medical weight management involves more than prescribing medication. A GP can help identify underlying health problems, assess treatment suitability, monitor progress and develop a sustainable weight-management plan.
At Crown St Medical Centre in Surry Hills, patients can discuss their weight-management concerns with our Surry Hills doctors team and receive an individualised medical assessment.
Depending on clinical circumstances, this may include:
- Reviewing weight history, BMI and waist circumference.
- Assessing blood pressure and metabolic health.
- Organising appropriate blood tests, such as HbA1c, cholesterol, liver and kidney function.
- Reviewing current medications and potential interactions.
- Discussing nutrition, physical activity and realistic weight-management goals.
- Monitoring treatment response and potential adverse effects.
- Providing ongoing support and arranging referrals where appropriate.
Regular reviews are important during treatment, particularly when doses are being increased. Ongoing monitoring also helps identify problems early and support long-term weight maintenance.
- Frequently Asked Questions
Is the Wegovy pill approved in Australia?
The TGA has registered four oral semaglutide tablet strengths: 1.5 mg, 4 mg, 9 mg and 25 mg. Registration does not necessarily mean immediate pharmacy availability.
How often do you take the Wegovy pill?
It is taken once daily, unlike injectable Wegovy, which is administered once weekly.
What is the recommended maintenance dose?
The US prescribing information recommends 25 mg once daily for adults. Treatment starts at 1.5 mg and gradually increases through 4 mg and 9 mg. Australian prescribing should follow the final Australian Product Information.
Can I take Wegovy with breakfast?
No. It should be taken on an empty stomach with plain water. Wait at least 30 minutes before eating, drinking other beverages or taking other oral medications, according to the US instructions.
Is the tablet as effective as the injection?
Clinical trials demonstrate substantial weight loss with both formulations. OASIS 4 reported an average 13.6% reduction with oral semaglutide, while STEP 1 reported 14.9% with injectable semaglutide. However, these were separate trials and do not establish equal effectiveness.
Can I switch from injections to tablets?
A switch may be appropriate for some patients, but it should be planned with a doctor. The formulations have different dosing schedules and should not be taken together.
Can I take Wegovy with Mounjaro?
NO. Concomitant use with other GLP-1 receptor agonists, including tirzepatide, is not recommended.
Will I regain weight after stopping Wegovy?
Weight regain is possible after discontinuation. Long-term weight management should include sustainable dietary and exercise habits and ongoing medical support.
Do I need a prescription?
Yes. Oral semaglutide is a prescription medicine and requires assessment by an appropriately qualified medical practitioner. It is NOT currently available at the time of writing this article.
Important information
This article is intended for general educational purposes and should not replace individual medical advice. Prescription treatment requires assessment of suitability, contraindications and potential adverse effects.
Clinical references:
- TGA – Australian Register of Therapeutic Goods (oral Wegovy registrations).
- OASIS 4 – Oral semaglutide 25 mg, New England Journal of Medicine, 2025.
- STEP 1 – Once-weekly semaglutide, New England Journal of Medicine, 2021.
- TGA – GLP-1 and dual GIP/GLP-1 receptor agonist safety information.
- Novo Nordisk – Wegovy US prescribing information and patient administration instructions.
Ready to discuss your health?
Book an Appointment Online at Crown St Medical Centre, Surry Hills Trusted Medical Practice
Last medically reviewed: 5 November 2026
Reviewed by: Doctors at Crown St Medical Centre – Surry Hills doctors/GPs
Location: Crown Street, Surry Hills NSW
